Disease
MASH / NASH
Metabolic dysfunction-associated steatohepatitis (MASH), formerly called nonalcoholic steatohepatitis (NASH), is the inflammatory and fibrotic form of MASLD that can progress to cirrhosis, liver failure, and hepatocellular carcinoma.
Coverage in progress. AssetMemo has not yet run its full census for MASH, Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis, so the assets listed for them are not complete.
Combined attributable cost
$303.2B+
Drug spend
$1.0B+
0% of total cost is drugs
Sum of 3 indications below.
Indications
MASH / NASH
$303.2B attributable cost
$64/patient drugs
All diagnosed and undiagnosed adult MASH/NASH severity strata (US estimate; upper-bound prevalence context) · US
MASH
Market size not yet sourced
All-stage · US
Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis
Market size not yet sourced
All-stage · US